About More|About More

About More

Home
About More

2012-2014: Founding and exploring
2015-2016: High-tech recognition, Government empowerment
2017-2018: Growing and thriving
2019-2021: Take advantage of the Bio-trend and keep the original intention, forge ahead, and start again
2023: Adhere to self-innovation and pursuit of excellence in biosynthesis
2024: To be continued

2012

Founding of Bontac Bio-Engineering (Shenzhen) Co., Ltd

2013

Obtainment of

* Support by financial funding from Shenzhen Science and Technology Innovation Program

2014

The world's first production line for whole-enzyme catalysis was established in BONTAC, realizing the production of NMN raw materials at the kilogram even ton level

* In cooperation with Harvard Medical School, BONTAC provided NMN raw materials for the anti-aging experiments of Professor David Sinclair who then successfully published the research results in “CELL” journal. On this basis, Joint Research Center of BONTAC and Harvard Medical School was subsequently established.

2015

Recognition as a high-tech enterprise in China

* Establishment of the first research institute for green biosynthesis in China

2016

BONTAC project of “Industrialization of the Core Raw Material Coenzyme” in Biocatalysis

2017

Top 100 Biotechnology company in Guangdong province

* Construction of enzyme manufacturing base with annual output of 1,000 tons

2018

Approval to set up the first provincial coenzyme engineering technology research center in China

* Obtainment of Shenzhen Science and Technology Progress Award

2019

Sales volume exceeding 100 million yuan

* Market share of NMN raw materials exceeding 60%-70%

2020

Implement of the 3rd generation whole-enzyme catalysis technology, with production capacity exceeding 100 tons.

* Serving more than 1,000 customers around the world

2021

Recognition as the specialized and sophisticated enterprises that produce new and unique products in Shenzhen

* The first to launch mass production of NMNH worldwide
* The top 100 innovative enterprise in China

2022

Merger, acquisition and reorganization of BONTAC by Qifu Capital

* Initial drafter of the group standard for NMN: Product Requirements and Test Methods for β-Nicotinamide Mononucleotide

* BONTAC NMN and Phosphatidylserine listed as "Guangdong Famous High-Tech Products in 2022*

*The launch of super factory project for BONTAC natural products in Fuyang, Anhui province

* Initial drafter of the group standard for NMN: Product Requirements and Test Methods for β-Nicotinamide Mononucleotide

* BONTAC NMN and Phosphatidylserine listed as "Guangdong Famous High-Tech Products in 2022

* Obtainment of the key special funds of 10 million for green bio-manufacturing from Department of Science and Technology of Guangdong Province

* Recognition as the “Synthetic Biology Enterprises” in Guangming district, and movement to the Synthetic Biology Industrial Park of Guangming Science City.

* BONTAC cooperation with Angel Yeast to launch the 200-ton NMN production project

* The launch of super factory project for BONTAC natural products in Fuyang, Anhui province

2023

2023 Deloitte China Life Sciences & Healthcare Rising Star

KPMG China's top 50 Biotech Innovation Enterprises in 2023

* Strategic cooperation with Shanghai Cell Therapy Group

* Major drafter of the group standard for NMNH: Quality Requirements and Test Methods for the Reduced Form of Nicotinamide Adenine Dinucleotide

* One drafter of the group standard for NAD: Product Requirements and Test Methods for Nicotinamide Adenine Dinucleotide

* NADH, Ginsenoside Rh2 and Stevioside RD listed as "Guangdong Famous High-Tech Products in 2023

* Health Industry Standard Innovation Award

* Health Industry Science and Technology Innovation Award

2024

BONTAC NMN raw materials obtain the certification of SELF GRAS by US FDA

* Excellent Brand in Synthetic Biology and Biological Manufacturing in 2024

* Annual Innovation Product Award

* Jury Special Prize in IFIA Japan 2024

* Natural Ingredients Award for Innovative Technology